Drugs / [177Lu]Lu-NeoB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06379217 | Jul 2024 → Sep 2026 overdue | prostate neuroendocrine neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05739942 | May 2024 → Aug 2027 expected | glioblastoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05870579 | Nov 2023 → Dec 2026 expected | breast cancer | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06247995 | Aug 2024 → Apr 2027 expected | breast cancer | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-NeoB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06247995 ↗ |
| Modality | Other / unclassified | “radioligand therapy” NCT05739942 ↗ |
| Route | Intravenous | “150mCi +/- 10% (iv infusion)” NCT06247995 ↗ |
| Target | GRPR | “high affinity to the GRPR and its ability to target the GRPR expressing tumor” NCT06247995 ↗ |